ALNY Alnylam Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALNY

Price (delayed)

$215.65

Market cap

$28.86B

P/E Ratio

35.35

Dividend/share

N/A

EPS

$6.1

Enterprise value

$30.14B

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 59
Relative Profitability: Rel. Profitability: 98

Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and ...

Highlights
The company's revenue has surged by 95% YoY and by 12% QoQ
The stock's price to earnings (P/E) is 88% less than its last 4 quarters average of 273.1
The company's quick ratio rose by 6% YoY but it fell by 3.1% QoQ
The company's gross margin fell by 4.7% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.alnylam.com
Peers: ARWR REGN SRPT OPK

Key stats

What are the main financial stats of ALNY

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
4.93%
1 week
-22.54%
1 month
-31.05%
1 year
-46.33%
YTD
-45.77%
QTD
-28.36%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$4.8B
Gross profit
$3.83B
Operating income
$999.78M
Net income
$807.99M
Gross margin
79.7%
Net margin
16.8%
The company's revenue has surged by 95% YoY and by 12% QoQ
The gross profit has soared by 86% YoY and by 10% from the previous quarter
The company's net income rose by 41% QoQ
Alnylam Pharmaceuticals's operating income has increased by 33% QoQ

Price vs fundamentals

How does ALNY's price correlate with its fundamentals

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
35.35
P/B
21.26
P/S
6
EV/EBIT
26.8
EV/EBITDA
25.55
EV/Sales
6.27
The stock's price to earnings (P/E) is 88% less than its last 4 quarters average of 273.1
ALNY's EPS is up by 41% since the previous quarter
ALNY's price to book (P/B) is 79% less than its last 4 quarters average of 98.2
The equity has grown by 26% from the previous quarter
The company's revenue has surged by 95% YoY and by 12% QoQ
ALNY's price to sales (P/S) is 68% lower than its 5-year quarterly average of 17.6 and 55% lower than its last 4 quarters average of 12.8

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
The ROE has soared by 138% YoY but it has contracted by 3.8% from the previous quarter
The return on assets has increased by 35% since the previous quarter
ALNY's return on invested capital is up by 27% since the previous quarter
ALNY's return on sales is up by 14% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 32% more than the total liabilities
The total assets has increased by 22% YoY and by 8% from the previous quarter
Alnylam Pharmaceuticals's current ratio has increased by 9% YoY but it has decreased by 2.6% from the previous quarter
The debt is 121% more than the equity
Alnylam Pharmaceuticals's debt to equity has plunged by 82% YoY and by 20% from the previous quarter
The equity has grown by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.